These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

988 related items for PubMed ID: 17302368

  • 1. A sustained virological response to interferon or interferon/ribavirin reduces hepatocellular carcinoma and improves survival in chronic hepatitis C: a nationwide, multicentre study in Taiwan.
    Yu ML, Lin SM, Chuang WL, Dai CY, Wang JH, Lu SN, Sheen IS, Chang WY, Lee CM, Liaw YF.
    Antivir Ther; 2006; 11(8):985-94. PubMed ID: 17302368
    [Abstract] [Full Text] [Related]

  • 2. Sustained virological response to interferon reduces cirrhosis in chronic hepatitis C: a 1,386-patient study from Taiwan.
    Huang JF, Yu ML, Lee CM, Dai CY, Hou NJ, Hsieh MY, Wang JH, Lu SN, Sheen IS, Lin SM, Chuang WL, Liaw YF.
    Aliment Pharmacol Ther; 2007 May 01; 25(9):1029-37. PubMed ID: 17439503
    [Abstract] [Full Text] [Related]

  • 3. Chronic hepatitis C virus infection in renal transplant: treatment and outcome.
    Sharma RK, Bansal SB, Gupta A, Gulati S, Kumar A, Prasad N.
    Clin Transplant; 2006 May 01; 20(6):677-83. PubMed ID: 17100715
    [Abstract] [Full Text] [Related]

  • 4. Risk factors for development of hepatocellular carcinoma in patients with chronic hepatitis C after sustained response to interferon.
    Ikeda M, Fujiyama S, Tanaka M, Sata M, Ide T, Yatsuhashi H, Watanabe H.
    J Gastroenterol; 2005 Feb 01; 40(2):148-56. PubMed ID: 15770398
    [Abstract] [Full Text] [Related]

  • 5. Combination of interferon and ribavirin in chronic hepatitis C: re-treatment of nonresponders to interferon.
    Di Bisceglie AM, Thompson J, Smith-Wilkaitis N, Brunt EM, Bacon BR.
    Hepatology; 2001 Mar 01; 33(3):704-7. PubMed ID: 11230751
    [Abstract] [Full Text] [Related]

  • 6. Reduced risk of hepatocellular carcinoma after interferon therapy in aged patients with chronic hepatitis C is limited to sustained virological responders.
    Imai Y, Tamura S, Tanaka H, Hiramatsu N, Kiso S, Doi Y, Inada M, Nagase T, Kitada T, Imanaka K, Fukuda K, Takehara T, Kasahara A, Hayashi N.
    J Viral Hepat; 2010 Mar 01; 17(3):185-91. PubMed ID: 19709362
    [Abstract] [Full Text] [Related]

  • 7. Response to interferon-based therapies in HIV-infected patients with chronic hepatitis C due to genotype 4.
    Soriano V, Núñez M, Sánchez-Conde M, Barreiro P, García-Samaniego J, Martín-Carbonero L, Romero M, González-Lahoz J.
    Antivir Ther; 2005 Mar 01; 10(1):167-70. PubMed ID: 15751774
    [Abstract] [Full Text] [Related]

  • 8. Combined interferon and ribavirin therapy for chronic hepatitis C in Taiwan.
    Lai MY.
    Intervirology; 2006 Mar 01; 49(1-2):91-5. PubMed ID: 16166795
    [Abstract] [Full Text] [Related]

  • 9. Favorable prognosis of chronic hepatitis C after interferon therapy by long-term cohort study.
    Imazeki F, Yokosuka O, Fukai K, Saisho H.
    Hepatology; 2003 Aug 01; 38(2):493-502. PubMed ID: 12883494
    [Abstract] [Full Text] [Related]

  • 10. Development of hepatocellular carcinoma in patients with chronic hepatitis C who had a sustained virological response to interferon therapy: a multicenter, retrospective cohort study of 1124 patients.
    Kobayashi S, Takeda T, Enomoto M, Tamori A, Kawada N, Habu D, Sakaguchi H, Kuroda T, Kioka K, Kim SR, Kanno T, Ueda T, Hirano M, Fujimoto S, Jomura H, Nishiguchi S, Seki S.
    Liver Int; 2007 Mar 01; 27(2):186-91. PubMed ID: 17311612
    [Abstract] [Full Text] [Related]

  • 11. Varying incidence of cirrhosis and hepatocellular carcinoma in patients with chronic hepatitis C responding differently to interferon therapy.
    Shindo M, Ken A, Okuno T.
    Cancer; 1999 May 01; 85(9):1943-50. PubMed ID: 10223234
    [Abstract] [Full Text] [Related]

  • 12. Risk factors for the development of hepatocellular carcinoma among patients with chronic hepatitis C who achieved a sustained virological response to interferon therapy.
    Tokita H, Fukui H, Tanaka A, Kamitsukasa H, Yagura M, Harada H, Okamoto H.
    J Gastroenterol Hepatol; 2005 May 01; 20(5):752-8. PubMed ID: 15853990
    [Abstract] [Full Text] [Related]

  • 13. Long-term outcome after interferon therapy in elderly patients with chronic hepatitis C.
    Arase Y, Ikeda K, Suzuki F, Suzuki Y, Saitoh S, Kobayashi M, Akuta N, Someya T, Koyama R, Hosaka T, Sezaki H, Kobayashi M, Kumada H.
    Intervirology; 2007 May 01; 50(1):16-23. PubMed ID: 17164553
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Prolonged-interferon therapy reduces hepatocarcinogenesis in aged-patients with chronic hepatitis C.
    Arase Y, Ikeda K, Suzuki F, Suzuki Y, Kobayashi M, Akuta N, Hosaka T, Sezaki H, Yatsuji H, Kawamura Y, Kobayashi M, Kumada H.
    J Med Virol; 2007 Aug 01; 79(8):1095-102. PubMed ID: 17597485
    [Abstract] [Full Text] [Related]

  • 18. A simple noninvasive index for predicting long-term outcome of chronic hepatitis C after interferon-based therapy.
    Yu ML, Lin SM, Lee CM, Dai CY, Chang WY, Chen SC, Lee LP, Lin ZY, Hsieh MY, Wang LY, Chuang WL, Liaw YF.
    Hepatology; 2006 Nov 01; 44(5):1086-97. PubMed ID: 17058238
    [Abstract] [Full Text] [Related]

  • 19. High body mass index is an independent risk factor for nonresponse to antiviral treatment in chronic hepatitis C.
    Bressler BL, Guindi M, Tomlinson G, Heathcote J.
    Hepatology; 2003 Sep 01; 38(3):639-44. PubMed ID: 12939590
    [Abstract] [Full Text] [Related]

  • 20. [Hepatitis C: epidemiology and therapy--with special reference to long-term prognosis after IFN therapy].
    Fujiyama S, Tanaka M.
    Rinsho Byori; 2000 Jan 01; 48(1):5-13. PubMed ID: 10756668
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 50.